Answers are grounded in this paper and cite their sources.
Therapeutic acceleration of endogenous liver regeneration remains a considerable unmet need for patients with acute or chronic liver injury. Among the pathways that coordinate regenerative responses, the Hippo pathway and its main components LATS1/2 kinases play a critical role by limiting YAP-dependent transcriptional programs associated with regeneration. Pharmacological inhibition of LATS1/2 thus represents a strategy to activate hepatic YAP signaling and promote tissue repair. Herein, we report the discovery of quinazoline-based LATS1/2 inhibitors derived from VT-02956 (1). Structure−activity relationship studies identified compound 24, a single-digit nanomolar LATS1/2 inhibitor with improved cellular YAP activation and metabolic stability. Compound 24 showed favorable kinase selectivity (S(35) = 0.04) and improved pharmacokinetics. In a partial hepatectomy mouse model, intraperitoneal administration of 24 activated YAP signaling, as evidenced by the upregulation of Cyr61 and Ankrd1, and significantly enhanced hepatocyte proliferation. These findings establish a medicinal chemistry foundation for developing LATS1/2 inhibitors as therapeutic agents for hepatic regeneration.
No takes yet. Share an insight, caveat, or question.
Reneesh et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: